Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Abatacept Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy 5.01.671

    Orencia (abatacept) for Intravenous Use

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 5.01.671 alerts

    Get alerted when Policy 5.01.671 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior authorization for intravenous abatacept for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and acute graft-versus-host disease prophylaxis; subcutaneous abatacept is handled under the pharmacy benefit.

    Policy Summary
    PayerBluecross Idaho
    PolicyOrencia (abatacept) for Intravenous Use
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateN/A
    Key ActionPrior authorization is required for intravenous abatacept under the medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearPrior-approval duration
    4Covered indication categories
    6 monthsTB screening window
    10 mg = 1 unitBillable unit conversion
    250 mg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Single-dose vial strength

    Coverage Criteria

    Initial Therapy: General Requirements

    Intravenous abatacept may be considered medically necessary for initial treatment when all general requirements are met.

    ALL of the following

    • Individual has had an inadequate therapeutic response to at least two (2) covered alternative products for the requested indication, if available, on either the pharmacy or medical benefit; or has a documented contraindication or intolerance to all available covered alternatives on the pharmacy and medical benefit for the requested indication. Pharmacy-covered alternatives apply only to members with Blue Cross of Idaho pharmacy benefits.
    • ONE of the following tuberculosis requirements

      • Tuberculosis (TB) screening test was completed within 6 months before initiating therapy and confirms no active tuberculosis.
      • If latent tuberculosis infection is present, treatment for the infection has been started before abatacept use.
      • Individual is switching from another targeted immune modulator that required TB screening at initiation, and there are no new TB risk factors; repeat screening is not required.
    • Abatacept is not being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.
    • Dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing.

    Initial Therapy: Covered Indications

    Initial intravenous abatacept therapy may be considered medically necessary for one of the following covered indications when the applicable criteria are met.

    ONE of the following indications

    • Rheumatoid arthritis (RA)

      • Individual is 18 years of age or older with moderately to severely active rheumatoid arthritis (RA)≥ 18 years
      • ONE of the following conventional-therapy requirements

        • Inadequate response to methotrexate titrated to the maximally tolerated dose.
        • If methotrexate is not tolerated or is contraindicated, documentation shows inadequate response to, intolerance of, or a contraindication to another conventional therapy option, such as sulfasalazine, leflunomide, or hydroxychloroquine.

    Continuation Therapy

    Continuation of intravenous abatacept may be considered medically necessary when all of the following are met.

    ALL of the following

    • Coverage criteria for initiation of abatacept therapy for the requested indication have previously been met.
    • There is clinically significant and functionally relevant improvement or stabilization in the clinical signs and symptoms of the disease.
    • Abatacept is not being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

    Medical Necessity Indications

    The following intravenous abatacept indications are listed as medically necessary when the applicable coverage criteria are met.

    ONE of the following medically necessary indications

    • Moderately to severely active rheumatoid arthritis (RA) in adults 18 years of age or older.
    • Moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in individuals 6 years of age or older.
    • Active psoriatic arthritis (PsA) in adults 18 years of age or older.
    • Prophylaxis of acute graft-versus-host disease (aGVHD) in individuals at least 2 years of age undergoing HSCT from a matched or 1 allele-mismatched unrelated donor, in combination with a calcineurin inhibitor and methotrexate.

    Intravenous abatacept is covered under the medical benefit and is subject to this policy. Subcutaneous abatacept is covered under the pharmacy benefit and is subject to applicable pharmacy-benefit utilization management or formulary requirements; subcutaneous or self-administered abatacept is outside the scope of this medical policy.

    Intravenous abatacept is FDA-approved for the listed rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and acute graft-versus-host disease prophylaxis uses. All other indications for intravenous abatacept are considered experimental or investigational and are not medically necessary.

    Continuation intravenous abatacept is not medically necessary when used in combination with topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, or biologic immunomodulators including TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, rituximab, or natalizumab. Continuation is also not medically necessary for active or untreated latent tuberculosis, hepatitis B, other active serious infections, a history of recurrent infections, when the continuation criteria are not met, or for all other indications. Repeat TB testing is not required for ongoing therapy.

    Initial Intravenous Abatacept

    Initial Intravenous Abatacept

    Initial intravenous abatacept may be considered medically necessary when all general requirements and one covered indication pathway are met.

    Initial intravenous abatacept

    • Covered-alternative requirement: The individual has had an inadequate therapeutic response to at least two covered alternative products for the requested indication, when available, on either the pharmacy or medical benefit; or has a documented contraindication or intolerance to all available covered alternatives on the pharmacy and medical benefits.At least 2 covered alternatives when available

      Pharmacy-covered alternatives apply only to members with Blue Cross of Idaho pharmacy benefits.

    • Tuberculosis requirement: Tuberculosis screening performed within 6 months before initiation confirms no active tuberculosis; or, if latent tuberculosis infection is present, treatment for the infection has started before abatacept; or, when switching from another targeted immune modulator that required tuberculosis screening at initiation and there are no new risk factors, repeat screening is not necessary.

    Continuation of Intravenous Abatacept

    Continuation of Intravenous Abatacept

    Continuation requests for intravenous abatacept may be considered medically necessary when all of the following are met.

    Continuation requirements: Coverage criteria for initiation of abatacept therapy for the requested indication were previously met; there is clinically significant and functionally relevant improvement or stabilization in clinical signs and symptoms of the disease; and abatacept is not used in combination with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

    Repeat tuberculosis testing is not required for ongoing therapy.

    Billing and Coding

    HCPCS CodesHCPCS
    J0129Injection, abatacept, 10 mg When drug is administered under the direct supervision of a physician. (Not for use when drug is self-administered).
    CPT CodesCPT
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    96366Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    96367Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    96368Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug).
    NDC CodesNDC
    0003-2187-13Orencia 250 mg single-use vial.
    ICD-10-CM CodesICD-10
    M05.00-M05.09Rheumatoid Arthritis (RA).
    M05.320-M06.39Rheumatoid Arthritis (RA).
    M06.80-M06.9Rheumatoid Arthritis (RA).
    M08.00-M08.9Juvenile Rheumatoid Arthritis (JRA) Juvenile Idiopathic Arthritis (pJIA).
    L40.50-L40.59Psoriatic Arthritis (PsA).
    D89.811Chronic Graft versus Host Disease.
    D89.812Chronic Graft versus Host Disease Acute Graft versus Host Disease (aGVHD).
    Service Place of ServiceRevenue
    Outpatient, physician officePlace of Service

    Authorization and Documentation Requirements

    Prior Authorization

    Medical-Benefit Prior Authorization Required

    Obtain medical-benefit prior authorization for intravenous abatacept (Orencia) before treatment. Approval may be issued for up to 1 year.

    • Applies to intravenous abatacept billed under the medical benefit.
    • Subcutaneous abatacept is outside this medical policy and is subject to pharmacy-benefit requirements.
    Step Therapy

    Covered Alternative Trial Required

    For the requested indication, document an inadequate therapeutic response to at least two covered alternative products when available, or documented contraindication or intolerance to all available covered alternatives on the pharmacy and medical benefits.

    • Pharmacy-benefit alternatives apply only when the member has Blue Cross of Idaho pharmacy benefits.
    • Document the alternative products tried and the response, contraindication, or intolerance.

    Clinical Background

    Abatacept is a selective T-cell costimulation modulator and soluble fusion protein composed of the extracellular domain of CTLA-4 linked to a modified human IgG1 Fc portion. It binds CD80 and CD86 and blocks their interaction with CD28, thereby reducing full T-cell activation. Intravenous abatacept is used for specified inflammatory and immune-mediated conditions, including rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and acute graft-versus-host disease prophylaxis in designated hematopoietic stem cell transplant settings.

    Key Definitions

    Abatacept
    DrugOrencia (abatacept)
    Pharmacologic classSelective T-cell co-stimulation modulator
    MechanismBinds CD80 and CD86, blocking interaction with CD28 and inhibiting full T-cell activation
    Molecular structureSoluble fusion protein consisting of the extracellular domain of CTLA-4 linked to the modified Fc portion of human IgG1
    aGVHD Prophylaxis
    DefinitionProphylaxis of acute graft-versus-host disease (aGVHD)
    Transplant setting

    Alternative Therapy Requirements

    StepRequirementDocumentation or Exception
    1For the requested indication, try at least two covered alternative products when available. The individual must have an inadequate therapeutic response to the alternatives.Document a contraindication or intolerance to all available covered alternatives when applicable. Indication-specific conventional therapy requirements must also be met, including failure, intolerance, or contraindication as specified.

    Prior Approval Duration

    Prior Approval Limit
    TherapyIntravenous abatacept
    Prior authorizationRequired under the medical benefit
    Approval durationUp to 1 year
    Approval conditionApplicable initiation or continuation criteria must be met

    Administration Setting

    Billing Rule

    Use the required office administration setting

    Administer intravenous abatacept under the direct supervision of a physician in an outpatient physician office setting. Use HCPCS J0129 for abatacept 10 mg; the code is not for self-administered drug use.

    • Listed intravenous infusion CPT codes are 96365, 96366, 96367, and 96368.
    • The listed place of service is outpatient, physician office.
    Policy Summary
    PayerBluecross Idaho
    PolicyOrencia (abatacept) for Intravenous Use
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateJan 1, 2026
    Last ReviewSep 25, 2025
    Next Review DateN/A
    Key ActionPrior authorization is required for intravenous abatacept under the medical benefit.
    SourceLink
    On This Page
    Coverage CriteriaInitial Intravenous AbataceptContinuation of Intravenous AbataceptBilling and CodingAuthorization and Documentation RequirementsClinical BackgroundKey DefinitionsAlternative Therapy RequirementsPrior Approval DurationAdministration Setting

    Polyarticular juvenile idiopathic arthritis (pJIA)

    • Individual is 6 years of age or older with active moderate to severe polyarticular juvenile idiopathic arthritis (pJIA)≥ 6 years
    • Inadequate response to, intolerance of, or a contraindication to conventional therapy, such as DMARDs including methotrexate, sulfasalazine, cyclosporine, or leflunomide.
  1. Psoriatic arthritis (PsA)

    • Individual is 18 years of age or older with active moderate to severe psoriatic arthritis (PsA)≥ 18 years
    • Inadequate response to, intolerance of, or a contraindication to conventional therapy, such as DMARDs including methotrexate, sulfasalazine, cyclosporine, or leflunomide.
  2. Acute graft-versus-host disease (aGVHD) prophylaxis

    • Individual is at least 2 years of age≥ 2 years
    • Individual is undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.
    • Abatacept is used in combination with a calcineurin inhibitor and methotrexate.
  3. Within 6 months before initiation
  4. Safety and dosing requirements: Abatacept is not used in combination with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator, and dosing is initiated in accordance with FDA-approved labeling and/or accepted drug compendia dosing.
  5. Covered indication pathway

    • Rheumatoid arthritis: The individual is 18 years of age or older with moderately to severely active rheumatoid arthritis and has had an inadequate response to methotrexate titrated to the maximally tolerated dose; or, if methotrexate is not tolerated or contraindicated, documentation shows inadequate response to, intolerance of, or contraindication to sulfasalazine, leflunomide, or hydroxychloroquine.Age >= 18 years
    • Polyarticular juvenile idiopathic arthritis: The individual is 6 years of age or older with active moderate to severe polyarticular juvenile idiopathic arthritis and has had inadequate response to, intolerance of, or a contraindication to conventional therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.Age >= 6 years
    • Psoriatic arthritis: The individual is 18 years of age or older with active moderate to severe psoriatic arthritis and has had inadequate response to, intolerance of, or a contraindication to conventional therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.Age >= 18 years
    • Acute graft-versus-host disease prophylaxis: The individual is at least 2 years of age, is undergoing hematopoietic stem cell transplantation from a matched or 1-allele-mismatched unrelated donor, and abatacept is used in combination with a calcineurin inhibitor and methotrexate.Age >= 2 years
  6. Documentation Required

    Document Conventional Therapy History

    Document inadequate response, intolerance, or contraindication to the applicable conventional therapy before requesting abatacept.

    • RA: inadequate response to methotrexate titrated to the maximally tolerated dose; if methotrexate is not tolerated or contraindicated, document the applicable conventional therapy history.
    • pJIA: document inadequate response, intolerance, or contraindication to conventional DMARD therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.
    • PsA: document inadequate response, intolerance, or contraindication to conventional DMARD therapy such as methotrexate, sulfasalazine, cyclosporine, or leflunomide.
    Documentation Required

    Tuberculosis Screening and Treatment Documentation

    Before initiation, document tuberculosis screening performed within 6 months and confirming no active tuberculosis, or document the applicable exception and treatment status.

    • If latent tuberculosis infection is present, document that treatment was started before abatacept.
    • TB screening is not required when switching from another targeted immune modulator that required screening at initiation, provided there are no new risk factors.
    • Repeat TB testing is not required for ongoing therapy.
    Documentation Required

    Indication-Specific Clinical Documentation

    Submit indication-specific clinical documentation supporting the diagnosis, age, disease activity, prior treatment, and requested regimen.

    • RA: age 18 or older with moderately to severely active rheumatoid arthritis.
    • pJIA: age 6 or older with active moderate to severe polyarticular juvenile idiopathic arthritis.
    • PsA: age 18 or older with active moderate to severe psoriatic arthritis.
    • aGVHD prophylaxis: age 2 or older, undergoing HSCT from a matched or 1 allele-mismatched unrelated donor, with abatacept used with a calcineurin inhibitor and methotrexate.
    • Indications other than FDA-approved uses are experimental/investigational and not medically necessary.
    Documentation Required

    Continuation Requires Documented Response

    For continuation requests, document that the initiation criteria for the requested indication were previously met and that treatment has produced clinically significant, functionally relevant improvement or stabilization in disease signs and symptoms.

    • Include the prior approval or clinical record establishing that initiation criteria were met.
    • Document current response, functional benefit, or meaningful stabilization.
    Billing Rule

    Verify Dosing and Administration

    Administer and request intravenous abatacept according to the indication-, age-, and weight-based FDA labeling or accepted compendia dosing.

    • Adult RA and PsA: loading doses at weeks 0, 2, and 4, then maintenance every 4 weeks; dose is 500 mg for weight under 60 kg, 750 mg for 60–100 kg, or 1,000 mg for weight over 100 kg.
    • pJIA: weight-based dosing with loading at weeks 0, 2, and 4 and maintenance every 4 weeks; use the adult dosing chart when weight is more than 75 kg, not to exceed 1,000 mg.
    • aGVHD prophylaxis: ages 2–5 years receive 15 mg/kg the day before transplant, then 12 mg/kg on days 5, 14, and 28; age 6 years and older receive 10 mg/kg, maximum 1,000 mg, on the day before transplant and days 5, 14, and 28.
    • Available form: 250 mg single-dose vial. Billable conversion: 10 mg = 1 unit.
    Denial Risk

    Review Concurrent Immunomodulator Therapy

    Do not use intravenous abatacept in combination with another biologic DMARD, targeted synthetic DMARD, or other immunomodulator, except where the FDA-approved aGVHD regimen specifically requires combination with a calcineurin inhibitor and methotrexate.

    • Noncovered combinations include topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, TNF antagonists, IL-23 inhibitors, IL-17 inhibitors, vedolizumab, ustekinumab, IL-1 inhibitors, IL-6 inhibitors, rituximab, and natalizumab.
    • The aGVHD prophylaxis regimen requires combination with a calcineurin inhibitor and methotrexate.
    Denial Risk

    Infection-Related Denial Risks

    Assess and document infection-related risks before and during treatment. Requests may be denied when the individual has active or untreated latent tuberculosis, hepatitis B, another active serious infection, or a history of recurrent infections.

    • Document TB status and any required latent-TB treatment before initiation.
    • Evaluate hepatitis B and other serious infections before treatment.
    • Repeat TB testing is not required for ongoing therapy unless otherwise clinically indicated.
    Denial Risk

    Uncovered Indication or Unmet Criteria

    Ensure the request is for an FDA-approved, covered indication and that all initiation or continuation criteria are met; otherwise intravenous abatacept is not medically necessary.

    • Covered FDA-approved uses include moderately to severely active RA in adults, active PsA in adults, moderately to severely active pJIA in patients age 6 or older, and aGVHD prophylaxis in patients age 2 or older undergoing qualifying HSCT.
    • Requests for all other indications are considered experimental/investigational and not medically necessary.
    • Continuation requests must demonstrate prior satisfaction of initiation criteria, clinically significant response or stabilization, and compliance with combination-therapy restrictions.
    Billing Rule

    Wrong Route: Pharmacy Benefit Applies

    Route the product to the correct benefit. Subcutaneous or self-administered abatacept is covered under the pharmacy benefit and is outside the scope of this medical policy.

    • Evaluate pharmacy-benefit prior authorization, formulary, and utilization-management requirements for subcutaneous or self-administered abatacept.
    • Do not submit subcutaneous or self-administered abatacept under this medical-benefit policy.
    Hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor
    Age requirementIndividual is at least 2 years of age
    Combination regimenUsed with a calcineurin inhibitor and methotrexate